-
These clinical research results of traditional Chinese medicine have been published in the top international journals
Time of Update: 2015-11-16
Because traditional Chinese medicine is mostly compound preparation, evidence-based medicine research has been the short board of traditional Chinese medicine At present, evidence-based medicine resea
-
Taiantang new drug "shezhishenhuang ointment" officially approved for market
Time of Update: 2015-11-16
Taiantang announced in the evening of November 16 that recently, the company received the approval document for supplementary drug application (approval document No.: 2015b01581) issued by the State F
-
Understanding of hepatitis drug market at home and abroad
Time of Update: 2015-11-16
Viral hepatitis is a group of infectious diseases including hepatitis A, B, C, D and E, affecting millions of people around the world About 1.5 million people die of hepatitis every year, mainly hepat
-
Wuxi Wuxi Pharmaceutical Co., Ltd. and Lilai Pharmaceutical Co., Ltd. jointly develop new small molecule drugs for cardiovascular diseases
Time of Update: 2015-11-11
Wuxi apptec and Lilly pharmaceutical announced strategic cooperation, and both sides will work together to develop, produce and commercialize a new small molecule drug in China The drug is an innovati
-
Zhongsheng Pharmaceutical Co., Ltd. raised 200 million yuan for the cooperative R & D project of small molecule chemical innovative drugs in Xianqiang Pharmaceutical Co., Ltd
Time of Update: 2015-11-10
Zhongsheng pharmaceutical announced on November 10 that it plans to increase no more than 88.0282 million shares per share by no less than 11.36 yuan, and raise about 1 billion yuan, which is mainly u
-
A brief history of China's new drug evolution: drawing a clear line from generic drugs
Time of Update: 2015-11-10
On November 4, 2015, the 17th session of the Standing Committee of the 12th National People's Congress passed a resolution authorizing the State Council to organize the reform of chemical drug registr
-
CDE Drug Evaluation Weekly Report (2015.11.1-2015.11.7)
Time of Update: 2015-11-09
In the review this week (2015.11.1-2015.11.7), 76 drugs (calculated according to the acceptance number, the same below) entered the review status, and the number slightly decreased compared with the p
-
The new drug review policy superimposed the approval for generic drug production to fall back
Time of Update: 2015-11-09
Since this year, a series of policies related to medicine have been implemented intensively, among which the policies on drug registration, review and approval are particularly noticeable In May, CFDA
-
CDE drug review weekly report (October 25, 2015 to October 31, 2015)
Time of Update: 2015-11-03
During the review this week (2015.10.25-2015.10.31), 91 drugs (calculated according to the acceptance number, the same below) entered the review status, and the number slightly decreased compared with
-
A new way of cooperation between Shanghai Institute of medicine and PerkinElmer in new drug research and development
Time of Update: 2015-10-29
On the morning of October 13, James Corbett, senior vice president of PerkinElmer company, global president of human health business unit, Kim Brian, chairman of human health business unit, and Joe Gu
-
Shanghai Institute of Medicine and PerkinElmer Co., Ltd. to carry out new drug research and development cooperation
Time of Update: 2015-10-28
October 28, 2015 - in the morning of October 13, James Corbett, senior vice president of PerkinElmer company, global president of human health business unit, Kim Brian, chairman of human health busine
-
Chongqing fuchuang 1.1 new antitumor drug furetinib succinate capsule and its API are approved clinically
Time of Update: 2015-10-28
Fuxing Pharmaceutical (02196 HK) announced that its holding subsidiary Chongqing fuchuang pharmaceutical research (Chongqing fuchuang) participated in the development of furetinib succinate capsule an
-
CDE drug review weekly report (October 18, 2015 to October 24, 2015)
Time of Update: 2015-10-27
In the review this week (2015.10.18-2015.10.24), 113 drugs (calculated according to the acceptance number, the same below) entered the review status, and the number slightly decreased compared with th
-
Saisheng Pharmaceutical Co., Ltd. plans to purchase 50 million yuan of Tianqi pharmaceutical's clinical approval for class 1.1 double target anti-tumor drugs
Time of Update: 2015-10-27
Beijing saisheng Pharmaceutical Co., Ltd announced on October 27 that the company plans to obtain 50 million yuan for the project of "transfer of clinical approval documents of HM-3 (antiangel peptide
-
Fengyuan pharmaceutical purchased 50 million yuan of new drugs for lung cancer
Time of Update: 2015-10-23
Fengyuan pharmaceutical announced on the evening of October 22 that the company and the University of science and technology of China signed the technology transfer contract for the "human recombinant
-
Suzhou HUYUN plans to raise 12 million yuan to develop new drugs
Time of Update: 2015-10-22
Suzhou HUYUN (833464) released the targeted issuance plan on the evening of October 21 The company plans to issue no more than 827600 shares to no more than 35 investors at a price of 14.5 yuan / shar
-
Disclosure of the ranking of "first generic" R & D capability of Chinese Pharmaceutical Enterprises
Time of Update: 2015-10-21
There is a kind of "generic drug", which is called class 3.1 new drug This kind of preparation or API has been listed abroad and has not entered China It is generally called "first generic" in the ind
-
CDE drug review weekly report (October 8, 2015 to October 17, 2015)
Time of Update: 2015-10-19
During the review this week (2015.10.8-2015.10.17), 148 drugs (calculated by acceptance number) entered the review status, with a significant increase in the number compared with last week Among them,
-
Inventory of only 10 domestic McAbs approved by CFDA
Time of Update: 2015-10-19
In 1986, OKT3, the world's first monoclonal antibody drug for the treatment of rejection in organ transplantation, was approved by the US FDA, which started the development of monoclonal antibody drug
-
Chongqing University of Arts and Science Ed new drugs won the first place in the team group of the final of the fourth China Innovation and entrepreneurship competition in biomedical industry
Time of Update: 2015-10-15
On October 9-12, LAN gang and Zhang Jin, vice presidents of the school, led the team, and Chongqing new medicine innovation team and Chongqing endangered aquatic resources protection team participated
